Cagrilintide: The Amylin Analog Behind the CagriSema Buzz
Few research peptides have generated as much discussion in 2026 as cagrilintide — the long-acting amylin analog at the heart of Novo Nordisk's CagriSema program. As metabolic research moves beyond single-receptor GLP-1 agonists, cagrilintide represents a different and complementary mechanism. Here's what the current research actually shows.
What is cagrilintide?
Cagrilintide is a synthetic, long-acting analog of amylin, a hormone co-secreted with insulin by the pancreas after meals. Native amylin helps regulate blood glucose and signals fullness, but it breaks down too quickly to work as a once-weekly compound. Cagrilintide is acylated to extend its half-life, allowing once-weekly subcutaneous administration in research settings.
How cagrilintide works
Amylin analogs act on brain receptors involved in appetite and satiety. In the literature, cagrilintide is described as reducing hunger, slowing gastric emptying, and increasing feelings of fullness — a mechanism distinct from, but complementary to, GLP-1 receptor agonists such as semaglutide. Because the two pathways differ, researchers have been especially interested in combining them.
CagriSema: pairing amylin with a GLP-1 agonist
CagriSema is a fixed-dose combination of cagrilintide and semaglutide — the first once-weekly pairing of a GLP-1 and an amylin analog. The rationale: engaging two complementary appetite pathways at once produces a larger effect than either alone.
What the 2026 trial data shows
In the Phase 3 REDEFINE 1 obesity trial, adults taking CagriSema lost an average of about 23% of body weight. In the REIMAGINE 2 trial in type 2 diabetes, CagriSema showed a superior HbA1c reduction of 1.91 percentage points and 14.2% weight loss at week 68 versus semaglutide alone. Novo Nordisk submitted a New Drug Application to the FDA in December 2025, with review expected during 2026.
Where cagrilintide fits in metabolic research
Cagrilintide reflects a clear trend: the field has moved from single agonists to dual and now triple agonists and combination therapies. For researchers tracking this space, cagrilintide stands out as the leading amylin analog and a building block of next-generation combination studies.
Handling and storage
Like other research peptides, cagrilintide is supplied as a lyophilized powder and reconstituted with bacteriostatic water before use. See our research guides for general reconstitution and storage practices.
Research use only. This article is educational and is not medical advice. The compounds discussed are not approved for human or veterinary use, consumption, or therapeutic application.